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Summary Formany years, bone graft substitutes have been used to reconstruct bone defects in
orthopedic and dental fields. However, synthetic bone substitutes such as hydroxyapatite or b-
tricalcium phosphate have no osteoinductive or osteogenic abilities. Bone tissue engineering has
also been promoted as an alternative approach to regenerating bone tissue. To succeed in bone
tissue engineering, osteoconductive scaffolding biomaterials should provide a suitable environ-
ment for osteogenic cells and provide local controlled release of osteogenic growth factors. In
addition, the scaffold for the bone graft substitute should biodegrade to replace the newly
formed bone. Recent advances in bone tissue engineering have allowed the creation of composite
scaffolds with tailored functional properties. This review focuses on composite scaffolds that
consist of synthetic ceramics and natural polymers as drug delivery carriers for alveolar bone
tissue engineering.
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Osteogenesis, osteoinduction, and osteoconduction are the
three essential elements of bone regeneration, along with
the final bonding between the host bone and the grafting
material, which is called osteointegration [1]. ‘‘Osteogen-
esis’’ is the process of new bone formation by osteoprogeni-* Corresponding author. Tel.: +81 3 3512 0404; fax: +81 3 3512 0571.
E-mail address: matsnot@tky.ndu.ac.jp (T. Matsuno).
1882-7616/$ — see front matter # 2010 Japanese Association for Denta
doi:10.1016/j.jdsr.2009.12.001tor cells living within the autograft. ‘‘Osteoinduction’’ on the
other hand is the stimulation and activation of host osteo-
progenitor cells from surrounding tissue [1]. ‘‘Osteocondu-
tion’’ describes the facilitation and orientation of blood-
vessel and the creation of the new Haversian systems into
the bone scaffold [2]. Finally ‘‘osteointegration’’ describes
the surface bonding between the host bone and the grafting
materials [2].
The advantage of an autograft is that it contains viable
osteoblasts and osteogenic progenitor cells that can contri-
bute to the formation of new bone [3]. In addition, the
autograft possesses the three essential elements that arel Science. Published by Elsevier Ireland. All rights reserved.
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grafts and xenografts, are believed to be osteoconductive,
but confer the risk of disease transmission and immune
rejection [4]. Therefore, autologous bone is generally con-
sidered the gold-standard graft material [5]. However, only a
minimal amount of bone tissue can be harvested for auto-
grafts, the harvesting procedure may lead to donor site
discomfort and morbidity, and it may be difficult to form
this tissue into the desired shape [6—8], a problem that is
particularly important in the craniofacial region.
To overcome these limitations, bone graft substitutes
have been used to reconstruct bone defects. Synthetic cera-
mics made from calcium phosphate have been used in den-
tistry and in orthopedics since the 1980s [9—11]. A bone graft
substitute should be osteoconductive, osteoinductive, bio-
compatible, biodegradable, structurally similar to bone, easy
to use, and cost-effective [1]. Hydroxyapatite (HA) and b-
tricalcium phosphate (b-TCP) are both well-known ceramics
that possess high tissue compatibility and osteoconductivity.
However, neither HA nor b-TCP has osteoinductive or osteo-
genic abilities, and HA usually shows minimal biodegradation
[12—14].
To overcome these problems, bone tissue engineering
has been promoted as an alternative approach to regen-
erate bone tissue. This approach combines cells capable of
osteogenic activity and osteoinductive signal molecules
with an appropriate material [15]. For bone tissue engi-
neering to succeed, osteoconductive scaffolding biomater-
ials must provide a suitable environment for the cells.
Furthermore, it is desirable that the scaffolds can control
the release of growth factors. Accordingly, biodegradable
composite scaffolds for bone tissue engineering have been
developed in combination with synthetic ceramics and
natural polymers. In this mini review, we focus on biode-
gradable osteoconductive composite scaffolds for alveolar
bone regeneration.
2. Osteoconductive scaffolds: HA and b-TCP
Commercial HA and b-TCP have been examined in terms of
suitability as a bone substitute in the clinical setting [16].
Radiological evaluation during clinical investigations of
implanted HA and b-TCP in humans has revealed satisfactory
osteoconductive qualities of both materials [17,18]. It is
known that ceramics with higher porosity and lower density
provide greater surface area for vascularization and bony
ingrowth. Furthermore, the regular and uniform surface
morphologies of HA and b-TCP affect cell proliferation and
differentiation [19,20]. When the ceramics are implanted
and attached to healthy bone, osteoids are produced directly
on the surfaces of the ceramic in the absence of a soft tissue
interface [1]. Thus, osteoconductive scaffolds such as HA and
b-TCP provide an appropriate environment for bone cells.
However, neither HA nor b-TCP have osteoinductive or osteo-
genic abilities, two factors that are important for successful
bone regeneration.
In addition, synthetic ceramics should be biodegradable to
support the reconstruction of new tissue without inflamma-
tion [21]. The current aim of the biological implant is to be
indistinguishable from the surrounding host bone [22]. After
implantation, a calcium phosphate compound such as b-TCP
undergoes remodeling and is eventually completely replacedby new bone. The degradation rate of b-TCP is 3—12 times
faster than HA [23]. Several animal experiments demon-
strated satisfactory biocompatibility of commercial b-TCP
as both biodegradation and bone formation began at an early
stage following implantation [24—26]. Moreover, it is also
possible to combine b-TCP with growth factors or bone
marrow aspirate, which can potentially accelerate the pro-
cess of bone regeneration [27—30].
Although the ceramics lack mechanical bone character-
istics, they gradually acquire mechanical strength similar to
cancellous bone after their incorporation [31,4]. In addition
to low load-bearing applications such as alveolar bone, it is
more important to have stability and the correct three-
dimensional shapes for functional and aesthetic reasons
[32]. With regard to shape, block and granule forms are
available for calcium phosphate ceramics. For alveolar bone
regeneration, the block shape is difficult to mold and adapt
into the three-dimensional structure of the bone defect
Thus, guided bone regeneration (GBR) using granule form
ceramics has been used for periodontal defects or alveolar
bone ridge augmentation. Such materials possess sufficient
mechanical strength to sustain the shape until it is replaced
by newly formed bone. Therefore, biodegradable granule
ceramics such as b-TCP have been used in alveolar bone
regeneration.
3. Natural polymers: collagen and gelatin
There are two types of biodegradable polymers: synthetic
polymers and natural polymers. Synthetic polymers are
widely used in biomaterial applications. Examples in tissue
engineering include aliphatic polyesters (polyglycolic acid
and poly-L-lactic acid), their copolymers (polylactic—cogly-
colic acid), and polycaprolactone. However, the chemicals
(additives, traces of catalysts, inhibitors) or monomers (gly-
colic acid, lactic acid) released during polymer degradation
may induce local and systemic host reactions that cause
clinical complications [32].
Natural-based polymers offer the advantage of being simi-
lar to biological macromolecules, and thus the biological
environment is better prepared to recognize and deal with
these polymers metabolically. Because of their similarity to
the extracellular matrix, natural polymers may also prevent
chronic inflammation or immunological reactions and toxicity,
which often occur with synthetic polymers [33]. Natural poly-
mers used in bone tissue engineering include collagen, gelatin,
fibrin, alginate, silk, hyaluronic acid, and chitosan [34]. Most
natural polymers are biocompatible, degradable, and readily
solubilized in physiological fluid, which can be used alone as a
growth factor delivery carrier or combinedwith other delivery
materials such as synthetic polymers and inorganic materials
[35]. This mini review focuses on collagen and gelatin as drug
delivery carriers for bone tissue engineering.
Collagen, as a natural polymer, is the most abundant
extracellular matrix protein and is readily isolated and pur-
ified from various animal species by enzyme treatment.
Because collagen type I is the main organic component
secreted by osteoblasts, which then become mineralized
at a later stage of bone development, collagen has been
actively investigated as a favorable artificial microenviron-
ment for bone ingrowth [36—39]. Type I collagen is not only a
major component of the bonematrix and useful as a carrier of
Table 1 Scaffolding biomaterials for bone tissue engineering.
Scaffold Osteoconduction Osteoinduction Osteogenesis Biodegradation Drug release
Autologous bone 3 3 3 2 0
HA 2 0 0 0 1
b-TCP 2 0 0 2 1
Collagen 1 0 0 3 2
Gelatin 1 0 0 3 3
Score: 0 (none) to 3 (excellent). HA: hydroxyapatite, TCP: tricalcium phosphate.
190 T. Matsuno et al.osteoblasts [40], but osteoblast cells have been shown to
successfully invade a collagen sponge with a porous HA frame
[41]. Collagen is easily degraded by the body and allows good
attachment to cells. On the other hand, collagen as a drug
delivery carrier has been fabricated as gels, nanofibers,
porous scaffolds, and films to prolong the release rate of
growth factors and increase the therapeutic effect of tissue
engineering approaches [22,42]. By incorporating transform-
ing growth factor-b1 into a dehydrothermally cross-linked
collagen sponge, the former was released in a biologically
active form as a result of sponge biodegradation, resulting in
enhanced bone repair of skull defects [43].
Gelatin is a natural polymer that is derived from collagen
and is commonly used for pharmaceutical and medical appli-
cations because of its biodegradability [44—47] and biocom-
patibility in physiological environments [48,49]. Various
forms of gelatin carrier matrices can be fabricated for con-
trolled-release studies [50]. The cross-linking density of
gelatin hydrogels has been shown to affect their degradation
rate in vivo, and the rate of biomolecule release from gelatin
carriers has been shown to have a similar profile, suggesting
that complexed gelatin/biomolecule fragments are released
by enzymatic degradation of the carrier in vivo [50]. Indeed,
the gelatin hydrogel or sponge can control the release of
growth factors to enhance their biological functions on bone
regeneration [51—54].
However, these natural polymers lack the initial mechan-
ical strength needed for weight bearing. It is a serious
disadvantage for implantation and makes it impossible to
use them alone for bone replacement in vivo [55]. Therefore,
additional support, such as a synthetic bone substitute, is
needed for bone regeneration.
4. Biodegradable composite scaffolds for
alveolar bone
Both ceramics and natural polymers have their own merits
and drawbacks (Table 1), and a better solution may be to
synergize the advantageous properties of both materials for
composite scaffolds. For example, the addition of collagen to
a ceramic structure can provide many additional advantages
for surgical applications: shape control, spatial adaptation,
increased particle and defect wall adhesion, and the ability
to favor clot formation and stabilization [56]. In addition, the
three-dimensional porous structure consisting of ceramic
granules and a collagen sponge provides an appropriate
spatial arrangement for osteogenetic cells as well as facil-
itating vascular invasion [57,58].
Many different composite forms such as sponges, gels,
films, and blocks have been developed using different meth-ods [32]. In alveolar bone regeneration by GBR, using sponges
or gels composites is desirable, as they easily fit into alveolar
bone defects. Sponge composites consisting of granule cera-
mics and natural polymers can simply be cut with scissors or a
sharp knife, and can therefore be easily molded for use for
various tissue disorders such as periodontal bone defects,
cyst cavities, and alveolar bone augmentation [57]. The
mechanical properties of the composites are relatively poor
in comparison to bone, although the graft site can be rein-
forced using membranes during GBR. Gradually, the collagen
of sponge composites degrades, and the remaining b-TCP
granules in the defect come into direct contact with the
newly formed bone. Finally b-TCP granules replace the
original bone structure during the remodeling process
[57,58]. In addition, these composite scaffolds can locally
release growth factors from collagen and gelatin, used as
drug delivery carriers, and enhance bone formation to treat
bone defects [43,51,53,54].
5. Conclusions
Autologous bone grafting is the gold standard for regenerat-
ing alveolar bone. Alternative strategies for bone tissue
engineering have also been developed involving three com-
ponents: a osteoconductive scaffold, osteogenic growth
factors, and osteogenic cells. However, it is difficult in
clinical dental practice to harvest osteogenic cells such as
mesenchymal stem cells, and the culture of the cells is also
impractical. In dental practice, one strategy for alveolar
bone regeneration is to induce maximum intrinsic healing
potential at the alveolar bone defect ‘‘in situ’’, applying a
selected ‘‘composite graft’’ that contains osteoinductive
growth factors along with an osteoconductive composite
scaffold. It is important to design the composite scaffold
to guide the osteoblasts to the regeneration site. When
developing a composite scaffold for alveolar bone regenera-
tion, the choice of the appropriate biomaterials (e.g., bio-
degradable synthetic ceramics and natural polymers) and
form (e.g., sponge or gel) is important, and should be based
on several parameters that address clinical needs and local
conditions. There are, however, unknown transmitting dis-
eases by natural polymers. The trends in tissue engineering
are heading for using animal product free materials. There-
fore, we should be selected materials carefully for safety
medicine.
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